A Phase 1 interventional study of Gamma-glutamylcysteine (GGC) in Repetitive Head Impacts, sponsored by Pravat Mandal. Recruiting at 1 site in United States. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Pravat Mandal · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 312 studies in Brain Injuries with a site in United States — 57 open to participants now, 69 under way, none of them phase 3. Brain Injuries · United States.
Among the 312 studies in Brain Injuries with a site in United States, this one is the 132nd largest by planned enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2026, is one of 16 in phase 1, reaches primary completion later than 38 of the 68 other live ones, and was the 288th registered.
947 studies on the registry are indexed under Brain Injuries; 236 are open to participants now.
Browse Brain Injuries studies →57 of the 312 studies in Brain Injuries with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Bridget LaMonica Ostrem, M.D., Ph.D. · Sites in United States
Ages 3 wk–20 wk
Children's Mercy Hospital Kansas City · Sites in United States
Ages up to 17
Peter C. Gerszten, MD · Sites in United States
Ages 21–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 153 Brain Injuries studies recruiting now, 76 (50%) set no upper age limit and 55 (36%) stop at 75 or younger; 39 take children under 18; 23 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
312 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 35 · Phase 3 9 · Phase 4 16
First in 1987; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 41 across 613 interventional studies indexed under Brain Injuries.
Median enrollment 42 across the 223 interventional studies, 85 across the 84 observational. Of the 207 that completed or were terminated, 67 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 312 have an industry lead sponsor. The 10 most frequent:
Pravat Mandal is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Pravat Mandal has 1 study filed under Brain Injuries — fewer than ten, so there is no comparison to draw.
19 of the studies in Brain Injuries with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485361University of California, Los AngelesfNIRS for Disorders of Consciousness | 2026-12 |
| NCT06725108University of ChicagoHemodynamic ABI Monitor | 2026-12-06 |
| NCT05708092Icahn School of Medicine at Mount SinaiNRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE) | 2026-12-31 |
| NCT06899971Boston Children's HospitalThe Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery | 2026-12-31 |
| NCT06855186Henry M. Jackson Foundation for the Advancement of Military MedicineSymptom-Targeted Approach to Rehabilitation for Concussion (STAR-C) | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 312 studies in Brain Injuries with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the:
This study is designed to evaluate the effects of GGC supplementation in patients with a history of repetitive head impacts (RHI) who are at risk for developing Traumatic Encephalopathy Syndrome (TES). The trial will include specific individuals who satisfy the eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will receive gamma-glutamyl cysteine (GGC) tablet orally 400mg (two times) per day once in the morning and once in the evening for 12 months.
Drug: Gamma-glutamylcysteine (GGC)
400mg tablet orally (two times) per day.
Also known as: GGC
Changes in brain glutathione levels (mM) in people with Repetitive Head Injury (RHI) using Magnetic Resonance Spectroscopy in pre and post supplementation.
(MRS) is a non-invasive imaging technique, to detect various neurochemical (e.g. glutathione) using MEGA-PRESS sequence from 1H MR spectroscopy.
Time frame: 12 months
Changes in baseline blood glutathione levels (µmol/l) in people with RHI due to GGC supplementation.
Time frame: 12 months
Changes in blood iron levels(ng/μl) in people with RHI due to GGC supplementation.
Time frame: 12 months
Correlation between glutathione and iron levels in the brain and blood with dysbiotic features of the gut microbiome in people with RHI.
Brain imaging, blood and stool samples will be collected to determine the correlation between glutathione and iron levels in the brain and blood with dysbiotic features of the gut microbiome in people with RHI.
Time frame: 12 months
Changes from baseline in the cognitive functions (immediate memory, visuospatial memory, language etc) using Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in people with RHI .
Interpretation: Higher scores \> 70 indicate greater cognitive function (PMID =36648917)
Time frame: 12 months
Changes in brain iron levels (ppb) in people with RHI using susceptibility mapping between pre and post supplementation.
Time frame: 12 months
Changes from baseline in the cognitive functions ( executive functions like attention, speed, and mental flexibility ) using Trail Making Test (TMT) A&B in people with RHI.
Scoring Method: The average scores are as follows: * Trail A - 29 seconds * Trail B - 75 seconds Interpretation: Higher scores indicate greater impairment
Time frame: 12 months
Changes from baseline in the cognitive functions and emotional well-being using Delis-Kaplan Executive Functioning System (D-KEFS) Color Word Interference test in people with a RHI
Interpretation: Higher score (\> 7) (PMID=21122190) indicates greater executive functions which includes cognitive abilities essential for tasks such as planning, problem-solving, and decision-making.
Time frame: 12 months
Changes from baseline in the cognitive functions and emotional well-being using Test of Premorbid Functioning (TOPF ) in people with RHI (PMID=36648917)
Interpretation of the results: Higher scores (\>45 above 315191110 indicate better cognitive and memory function.
Time frame: 12 months
Changes from baseline in the cognitive functions and emotional wellbeing using Brief Symptom Inventory (BSI-18) (self-report) in people RHI .
Scoring Method: Each item is scored on a 0-4 scale, with the total score indicating the severity of distress. Interpretation: Higher total scores indicate greater severity of psychological distress.
Time frame: 12 months
Changes from baseline in the cognitive functions and emotional well-being using PROMIS Cognitive Function -Short Form 8a (self-report) tool in people RHI.
Scoring Method: Raw Score: 8-40 Interpretation: Lower scores on this measure indicate greater subjective cognitive difficulty.
Time frame: 12 months
Plan to share: Yes — Clinical study report data will be provided after the study data is analyzed and published. A comprehensive report will be sent to the IRB. The respective agency will be reported accordingly. Requests for the release of data must be submitted in writing to the PI, clearly stating the purpose of the request, the specific data needed, and the intended use. The PI, in collaboration with the research team, will review each request to ensure compliance with institutional policies, ethical standards, and any relevant data use agreements.
Supporting information: Clinical study report
Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gamma-glutamylcysteine